ClinicalTrials.gg
RecruitingNCT06257394VHR ALLUpdated Jul 29, 2026

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

A Phase 2 interventional study of Dasatinib(Sprycel) arm and Non-Dasatinib(Sprycel) arm in Acute Lymphoblastic Leukemia, Pediatric, sponsored by Hyoung Jin Kang. Recruiting at 10 sites in South Korea. Open to participants aged 1 Year to 19 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Hyoung Jin Kang · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
1 Year to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 5 open to participants now, 10 under way, 2 of them phase 3. Dasatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
13th of 41
74 · median 51
Started
2024
with 1 other
Phase 2
19 of 42
3 open now
Registered
40th of 42
by date

Among the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 13th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 in phase 2, and was the 40th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

5 of the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dasatinib

Dasatinib: first FDA approval 2006 (SPRYCEL), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

Very high-risk acute lymphoblastic leukemia

Read the detailed description
  • Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)

    • Morphologic Complete Remission after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3

      1. If Minimal Residual Disease \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using High Dose Methotrexate, High Dose Cytarabine → DI(Delayed Intensification) #1 → IM(Interim Maintenance) #2 → DI(Delayed Intensification) #2 → Maintenance
      2. If Minimal Residual Disease or qPCR(Quantitative Polymerase Chain Reaction) positivie after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT(Hematopoietic Stem Cell Transplantation)
    • M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT(Hematopoietic Stem Cell Transplantation)

      1. If Minimal Residual Disease \& qPCR(Quantitative Polymerase Chain Reaction) not detected after the post-consolidation #1 : Consolidation #3 using High Dose Methotrexate, HD Cytarabine
      2. If Minimal Residual Disease or qPCR(Quantitative Polymerase Chain Reaction) positivie after the post-reinduction : Consolidation #3 using Blinatumomab

        • In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.
  • Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction

    • Morphologic Complete Remission after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3

      1. If Minimal Residual Disease not detected after the post-consolidation #1 : Consolidation #3 using High Dose Methotrexate, High Dose Cytarabine → Allogeneic HSCT(Hematopoietic Stem Cell Transplantation)
      2. If Minimal Residual Disease positivie after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT(Hematopoietic Stem Cell Transplantation)
    • M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT(Hematopoietic Stem Cell Transplantation)

      1. If Minimal Residual Disease not detected after the post-consolidation #1 : Consolidation #3 using High Dose Methotrexate, High Dose Cytarabine
      2. If Minimal Residual Disease positivie after the post-reinduction : Consolidation #3 using Blinatumomab
03

Conditions studied

  • Acute Lymphoblastic Leukemia, Pediatric

Keywords

  • VHR ALL
  • NGS-MRD
04

Who can participate

Ages eligible
1 Year to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:

    • Philadelphia chromosome-positive t(9;22)(q34;q11) or
    • Patients with failed remission who had blast > 5% on bone marrow test after initial remission induction therapy or
    • Hypodiploidy (Number of chromosomes \< 44 (less than 44)) or
    • E2A-HLF(Hepatic Leukemia Factor) translocation-positive or
    • When the prognosis is judged to be poor according to NGS-MRD results among high-risk ALL patients (i) In B-ALL, the NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) after consolidation therapy is 0.01% or more, and the NGS-MRD followed during interim maintenance treatment is also 0.01% or more, (ii) In T-ALL, NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) is more than 0.01% after consolidation therapy

Exclusion criteria

Exclusion Criteria:

  • Participants with to medications
  • When the study participant or their legal representative withdraws consent
  • Pregnant or lactating women (patients of require adequate during the study period)
  • Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other interventional studies other than this protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    [Arm A, Dasatinib(Sprycel) Arm]

    ▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.) * Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3 1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT * M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT 1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.

    Drug: Dasatinib(Sprycel) arm

  • Experimental
    [Arm B, Non-Dasatinib(Sprycel) Arm]

    ▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction * Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3 1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT * M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT 1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab

    Drug: Non-Dasatinib(Sprycel) arm

Interventions

  • DrugDasatinibStudies of DasatinibDasatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.) * Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3 1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT * M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT 1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.

  • DrugDasatinibStudies of DasatinibDasatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction * Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3 1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT * M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT 1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab

06

What researchers measure

Primary outcomes

  1. Event free survival

    Time frame: Up to 5 years

Secondary outcomes

  1. Overall survival

    The time until defined by date of all-cause mortality from the date of 1st infusion

    Time frame: Up to 5 years

  2. Recurred rate

    As the period from enrollment to disease progression/recurrence

    Time frame: Up to 5 years

  3. Death rate related to infusion

    The time until defined by date of drug-related mortality from the date of 1st infusion

    Time frame: Up to 5 years

  4. Adverse Event

    Time frame: From Day 1 of the clinical trial to 28 days after last drug administration

  5. The rate of Hematopoietic stem cell transplantation

    The rate of Hematopoietic stem cell transplantation after the Induction and consolidation therapy

    Time frame: Up to 5 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2034, 122 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 122 months is above that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 14, 2024
StartActual
Oct 20, 2024
Primary completionEst.
Dec 31, 2034
CompletionEst.
Dec 31, 2034
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06257394
Lead sponsor
Hyoung Jin Kang
Collaborators
Asan Medical Center, Samsung Medical Center, Severance Hospital, Pusan National University Yangsan Hospital, Seoul St. Mary's Hospital, Chonnam National University Hospital, Chungnam National University Hospital, Kyungpook National University Chilgok Hospital, Jeju National University Hospital
Responsible party
Hyoung Jin Kang (Professor, Seoul National University Hospital) — Sponsor-investigator
First posted
Feb 14, 2024
Start date
Oct 20, 2024
Primary completion
Dec 31, 2034 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Jul 29, 2026

Study contacts

Hyoung Jin Kang, Ph.D
Contact
kanghj@snu.ac.kr
+82-2-2072-3452
Hyoung Jin Kang
Contact
kanghj@snu.ac.kr
+82220723452

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dasatinib

Start the discussion